Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
AstraZeneca
Express Scripts
Baxter
Mallinckrodt

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Sacubitril

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Sacubitril?

Sacubitril is an investigational drug.

There have been 56 clinical trials for Sacubitril. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Heart Failure, Myocardial Infarction, and Hypertension. The leading clinical trial sponsors are Novartis Pharmaceuticals, The Cleveland Clinic, and Brigham and Women's Hospital.

There are forty-four US patents protecting this investigational drug and four hundred and ninety-three international patents.

Recent Clinical Trials for Sacubitril
TitleSponsorPhase
Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection FractionFlinders UniversityPhase 3
Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)Massachusetts General HospitalPhase 2
Effect of Sacubitril/Valsartan on Reduced RVEF in Patients With CTDRenJi HospitalPhase 4

See all Sacubitril clinical trials

Clinical Trial Summary for Sacubitril

Top disease conditions for Sacubitril
Top clinical trial sponsors for Sacubitril

See all Sacubitril clinical trials

US Patents for Sacubitril

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sacubitril   Start Trial Organic compounds INTRA-CELLULAR THERAPIES, INC. (New York, NY)   Start Trial
Sacubitril   Start Trial Synthetic linear apelin mimetics for the treatment of heart failure NOVARTIS AG (Basel, CH)   Start Trial
Sacubitril   Start Trial Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
Sacubitril   Start Trial Compositions and methods for treating heart disease and/or injury CASE WESTERN RESERVE UNIVERSITY (Cleveland, OH) OREGON HEALTH & SCIENCE UNIVERSITY (Portland, OR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sacubitril

Drugname Country Document Number Estimated Expiration Related US Patent
Sacubitril World Intellectual Property Organization (WIPO) 2016022836 2034-08-07   Start Trial
Sacubitril Argentina 093559 2032-11-20   Start Trial
Sacubitril China 105007928 2032-11-20   Start Trial
Sacubitril European Patent Office 2922559 2032-11-20   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Moodys
Mallinckrodt
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.